The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure

Bibliography

• McMurray JJ, Adamopoulos S, Anker SD, et al. Task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9
   PubMed Web of Science ®Google Scholar
• Voors AA, de Jong RM. Treating diastolic heart failure. Heart 2008;94:971-2
   PubMed Web of Science ®Google Scholar
• Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-32
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-66; 1667-75
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71
   PubMed Web of Science ®Google Scholar
• van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur Heart J 2005;26:2361-7
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21
   PubMed Web of Science ®Google Scholar
• Krum H, Massie B, Abraham WT, et al. ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-14
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Pitt B, Latini R, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24
   PubMed Web of Science ®Google Scholar
• Baran D, Horn EM, Hryniewicz K, Katz SD. Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure. Drugs 2000;60:997-1016
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8
   PubMed Web of Science ®Google Scholar
• Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs 2003;63:2185-202
   PubMed Web of Science ®Google Scholar
• Cuculi F, Erne P. Combined neutral endopeptidase inhibitors. Expert Opin Investig Drugs 2011;20(4):457-63
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356(9230):615-20
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6
   PubMed Web of Science ®Google Scholar
• Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-11
   PubMed Web of Science ®Google Scholar
• Segura J, Ruilope LM. Dual-acting angiotensin receptor-neprilysin inhibition. Curr Hypertens Rep 2011;13(1):74-8
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401-14
   PubMed Web of Science ®Google Scholar
• Baxter GF. The natriuretic peptides. Basic Res Cardiol 2004;99:71-5
   PubMed Web of Science ®Google Scholar
• Elmarakby AA, Morsing P, Pollock JS, Pollock DM. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats. Vascul Pharmacol 2003;40:253-9
   PubMed Web of Science ®Google Scholar
• Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure. JAMA 2013;309(11):E1-E11
   Google Scholar
• Freyer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-55
   PubMed Web of Science ®Google Scholar
• Timmermans PB, Smith RD. A new class of therapeutic agents: the angiotensin II receptor antagonists. Cardiologia 1994;39(Suppl 1):397-400
   PubMedGoogle Scholar
• Waldmeier F, Flesch G, Müller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27:59-71
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Böhm M, et al. Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-66
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, and on behalf of the PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; doi:10.1093/eurjhf/hft052
   Web of Science ®Google Scholar